Drug Trial Radar · NCT04543591
Ravulizumab in Thrombotic Microangiopathy After Hematopoietic Stem Cell Transplant
Last checked: Nov 20, 2026Latest source record: Nov 4, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
148
Actual
Start
Dec 10, 2020
Primary completion
Sep 19, 2025
Study completion Mar 20, 2026
Sponsor
- Lead sponsor
- Alexion Pharmaceuticals, Inc.AstraZeneca (AZN)
- Sponsor type
- Industry
- First posted
- Sep 10, 2020
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 12 years, up to 100 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study will evaluate the efficacy, safety, pharmacokinetics, and pharmacodynamics of ravulizumab in adult and adolescent participants with hematopoietic stem cell transplant-associated thrombotic microangiopathy (HSCT-TMA). In Stage 1, an open-label, single-arm period, the dosing regimen will be confirmed. In Stage 2, participants will be randomized to receive either blinded ravulizumab plus best supportive care or matching placebo plus best supportive care. The treatment period is 26 weeks (open-label for Stage 1, and randomized, double-blind, and placebo-controlled for Stage 2) followed by a 26-week follow-up period.
Conditions
- Thrombotic Microangiopathy
Interventions
RavulizumabBiological
Weight-based doses of ravulizumab will be administered intravenously as loading dose regimen followed by maintenance dosing every 8 weeks.
PlaceboOther
Matching placebo
Best supportive careOther
Participants will receive medications, therapies, and interventions per standard hospital treatment protocols (unless specifically prohibited by the protocol).
Primary outcomes
What the sponsor says the trial is designed to measure.
- Stage 2: Proportion of Participants With Event-free Survival During the 26-week Treatment PeriodTime frame: Up to Week 26
Locations
66 sites in 17 countries. Site status is shown where the registry gives one.
Research Site
Tampa, Florida
Research Site
Grosse Pointe Farms, Michigan
Research Site
Durham, North Carolina
Research Site
Pittsburgh, Pennsylvania
Research Site
Seattle, Washington
Research Site
Parkville, Australia
Research Site
Bruges, Belgium
Research Site
Brussels, Belgium
Research Site
Chênée, Belgium
Research Site
Yvoir, Belgium
Research Site
Cerqueira César, Brazil
Research Site
Florianópolis, Brazil
Research Site
Jaú, Brazil
Research Site
Porto Alegre, Brazil
Research Site
Porto Alegre, Brazil
Research Site
Rio de Janeiro, Brazil
Research Site
São José do Rio Preto, Brazil
Research Site
São Paulo, Brazil
Research Site
Calgary, Alberta, Canada
Research Site
Suzhou, China
Research Site
Tianjin, China
Research Site
Angers, France
Research Site
La Tronche, France
Research Site
Nice, France
Research Site
Hamburg, Germany
Research Site
Ulm, Germany
Research Site
Athens, Greece
Research Site
Pátrai, Greece
Research Site
Thessaloniki, Greece
Research Site
Halfa, Israel
Research Site
Ramat Gan, Israel
Research Site
Roma, Italy
Research Site
Udine, Italy
Research Site
Akita, Japan
Research Site
Anjo, Japan
Research Site
Chiba, Japan
Research Site
Fukushima, Japan
Research Site
Isehara-shi, Japan
Research Site
Kurashiki-shi, Japan
Research Site
Minatoku, Japan
Showing 40 of 66 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.